Literature DB >> 29251360

Laboratory characteristics of ischemic stroke patients with atrial fibrillation on or off therapeutic warfarin.

Raghav V Aachi1, Lee A Birnbaum1,2, Christopher H Topel1, Ali Seifi2, Shaheryar Hafeez2, Réza Behrouz1.   

Abstract

BACKGROUND: In patients with atrial fibrillation (AF), despite adequate anticoagulation, ischemic stroke (IS) is an uncommon yet concerning occurrence. HYPOTHESIS: Specific laboratory parameters may affect the efficacy of warfarin despite therapeutic international normalized ratio (INR) in patient with AF who present with IS.
METHODS: We used the database from a multicenter clinical trial to identify AF patients who presented with IS. We trichotomized the cohort into patients with therapeutic INR on warfarin, subtherapeutic INR on warfarin, and on no anticoagulants. We then compared baseline laboratory characteristics and other baseline features among the groups.
RESULTS: Patients with therapeutic INR presented with higher serum creatinine (P = 0.01) and blood urea nitrogen (P = 0.02) and lower glomerular filtration rates (P = 0.001) compared with other groups. Other laboratory parameters were not different among the 3 groups. Patients with therapeutic INR also presented with milder stroke symptoms (P = 0.01). Medical history of the 3 groups was not different, except for history of valvular heart disease, which was more prevalent in patients with therapeutic INR (P = 0.004). In-hospital mortality rates and 90-day disability were not different among the 3 groups.
CONCLUSIONS: AF patients who presented with IS on therapeutic warfarin had higher average serum creatinine and blood urea nitrogen, and lower glomerular filtration rates, compared with others. Impaired renal function may be a factor contributing to occurrence of IS in AF patients despite adequate anticoagulation. Larger, targeted studies are needed to confirm these findings.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  Acute Stroke; Anticoagulation; Atrial Fibrillation; International Normalized Ratio; Warfarin

Mesh:

Substances:

Year:  2017        PMID: 29251360      PMCID: PMC6490348          DOI: 10.1002/clc.22838

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  21 in total

1.  Risk factors for cerebral ischemic events in patients with atrial fibrillation on warfarin for stroke prevention.

Authors:  Maurizio Paciaroni; Giancarlo Agnelli; Walter Ageno; Valeria Caso; Francesco Corea; Alessia Lanari; Andrea Alberti; Paolo Previdi; Marta Fedele; Giorgia Manina; Cristina Vedovati; Michele Venti; Antonia M R Billeci; Maurizio Batta; Luca Galli; Giorgio Silvestrelli
Journal:  Atherosclerosis       Date:  2010-06-15       Impact factor: 5.162

2.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  Circulation       Date:  2014-03-28       Impact factor: 29.690

3.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.

Authors:  B F Gage; A D Waterman; W Shannon; M Boechler; M W Rich; M J Radford
Journal:  JAMA       Date:  2001-06-13       Impact factor: 56.272

4.  Culprit factors for the failure of well-conducted warfarin therapy to prevent ischemic events in patients with atrial fibrillation: the role of homocysteine.

Authors:  Daniela Poli; Emilia Antonucci; Emanuele Cecchi; Rossella Marcucci; Agatina Alessandrello Liotta; Anna Paola Cellai; Meri Lenti; Gian Franco Gensini; Rosanna Abbate; Domenico Prisco
Journal:  Stroke       Date:  2005-09-22       Impact factor: 7.914

Review 5.  How to define valvular atrial fibrillation?

Authors:  Laurent Fauchier; Raphael Philippart; Nicolas Clementy; Thierry Bourguignon; Denis Angoulvant; Fabrice Ivanes; Dominique Babuty; Anne Bernard
Journal:  Arch Cardiovasc Dis       Date:  2015-07-14       Impact factor: 2.340

6.  Laboratory characteristics of ischemic stroke patients with atrial fibrillation on or off therapeutic warfarin.

Authors:  Raghav V Aachi; Lee A Birnbaum; Christopher H Topel; Ali Seifi; Shaheryar Hafeez; Réza Behrouz
Journal:  Clin Cardiol       Date:  2017-12-18       Impact factor: 2.882

7.  Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.

Authors:  Walter N Kernan; Bruce Ovbiagele; Henry R Black; Dawn M Bravata; Marc I Chimowitz; Michael D Ezekowitz; Margaret C Fang; Marc Fisher; Karen L Furie; Donald V Heck; S Claiborne Clay Johnston; Scott E Kasner; Steven J Kittner; Pamela H Mitchell; Michael W Rich; DeJuran Richardson; Lee H Schwamm; John A Wilson
Journal:  Stroke       Date:  2014-05-01       Impact factor: 7.914

8.  Dehydration in hospital-admitted stroke patients: detection, frequency, and association.

Authors:  Anne Rowat; Catriona Graham; Martin Dennis
Journal:  Stroke       Date:  2011-12-08       Impact factor: 7.914

9.  Warfarin in atrial fibrillation patients with moderate chronic kidney disease.

Authors:  Robert G Hart; Lesly A Pearce; Richard W Asinger; Charles A Herzog
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-08       Impact factor: 8.237

10.  Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.

Authors: 
Journal:  Arch Intern Med       Date:  1994-07-11
View more
  1 in total

1.  Laboratory characteristics of ischemic stroke patients with atrial fibrillation on or off therapeutic warfarin.

Authors:  Raghav V Aachi; Lee A Birnbaum; Christopher H Topel; Ali Seifi; Shaheryar Hafeez; Réza Behrouz
Journal:  Clin Cardiol       Date:  2017-12-18       Impact factor: 2.882

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.